Search Within

Patricia Myskowski

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (4)
Groups
  1. Department of Medicine (11)
  2. Dermatology (11)
  3. Dermatology Service (11)
  4. Division of Subspecialty Medicine (11)
  5. Epidemiology and Biostatistics (11)
  6. Population Sciences Research Program (11)

More Groups

People
  1. Alison Moskowitz (7)
  2. Steven Horwitz (7)
  3. Ahmet Dogan (5)
  4. Ariela Noy (5)
  5. Allan Halpern (4)
  6. Colin Begg (4)

More People

Years
  1. 2021 (2)
  2. 2020 (1)
  3. 2019 (1)
  4. 2018 (1)
  5. 2017 (1)
  6. 2016 (1)

More Years

Publications
  1. Blood (3)
  2. American Journal of Epidemiology (1)
  3. Cancer Immunology Research (1)
  4. Cancer Research (1)
  5. European Journal of Cancer Prevention (1)
  6. Hematological Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (3)
  2. American Society of Hematology (3)
  3. Elsevier Science, Inc. (1)
  4. Mosby Elsevier (1)
  5. Oxford University Press (1)
  6. Wiley Blackwell (1)

More Publishers

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Multispectral immunofluorescence identifies pS6 as a biomarker of intrinsic resistance to ruxolitinib in patients with relapsed/refractory T-cell lymphomas
    Meeting Abstract

    Ghione, P.; Moskowitz, A.; Kumar, P.; Knezevic, A.; Seshan, V.; Jacobsen, E.; Ruan, J.; Schatz, J.; Noor, S.; Myskowski, P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin
    Journal Article

    Kheterpal, M. K.; Dai, J.; Geller, S.; Pulitzer, M.; Ni, A.; Myskowski, P. L.; Moskowitz, A.; Kim, J.; Hong, E. K.; Fong, S.; more...
    Journal of the American Academy of Dermatology (2019)

    Fulltext@MSK | Save
  • Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile
    Journal Article

    Querfeld, C.; Leung, S.; Myskowski, P. L.; Curran, S. A.; Goldman, D. A.; Heller, G.; Wu, X.; Kil, S. H.; Sharma, S.; Finn, K. J.; more...
    Cancer Immunology Research (2018)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Estimating the relative risk of developing melanoma in INK4A carriers
    Journal Article

    Berwick, M.; Orlow, I.; Mahabir, S.; Myskowski, P.; Coit, D.; Brady, M. S.; Roy, P.; Song, Y.; Canchola, R.; Barz, A.; more...
    European Journal of Cancer Prevention (2004)

    Fulltext@MSK | Save
  • Estimating risk for melanoma with an INK4A mutation
    Meeting Abstract

    Berwick, M.; Begg, C.; Mahabir, S.; Coit, D.; Brady, M. S.; Myskowski, P.; Roy, P.; Song, Y.; Canchola, R.; Orlow, I.
    American Journal of Epidemiology (2001)

    Fulltext@MSK | Save
  • Estimation of melanoma risk due to germline mutations in CDKN2A(INK4A): A pilot study
    Meeting Abstract

    Elahi, A.; Betwick, M.; Begg, C.; Lewis, D.; Mahabir, S.; Bolognia, J.; Myskowski, P.; Halpern, A.; Brady, M. S.; Coit, D.; more...
    Proceedings of the American Association for Cancer Research Annual Meeting (1999)

    Fulltext@MSK | Save